Evidence map›Paper›PMID 24386373›Full record

Trial reportPloS one2013

WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients.

Yanhong Liu, Hashem B El-Serag, Li Jiao, Juseog Lee, David Moore, Luis M Franco, Shahriar Tavakoli-Tabasi, Spiridon Tsavachidis, Jill Kuzniarek, David J Ramsey and 1 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Review
  3. Wnt signaling in liver regeneration, disease, and cancer.Clinical and molecular hepatology · 2023
    Review
  4. Review
  5. Wnt-β-catenin signalling in liver development, health and disease.Nature reviews. Gastroenterology & hepatology · 2019
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yanhong LiuDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America ; Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States of America.
Hashem B El-SeragSection of Gastroenterology and Hepatology, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America ; Clinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuEST), Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America ; Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States of America ; Texas Medical Center Digestive Disease Center, Houston, Texas, United States of America.
Li JiaoSection of Gastroenterology and Hepatology, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America ; Clinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuEST), Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America ; Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States of America ; Texas Medical Center Digestive Disease Center, Houston, Texas, United States of America ; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States of America.
Juseog LeeDepartment of Systems Biology, MD Anderson Cancer Center, Houston, Texas, United States of America.
David MooreDepartment Molecular and Cell Biology and Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
Luis M FrancoDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, United States of America.
Shahriar Tavakoli-TabasiSection of Infectious Diseases, Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas, United States of America.
Spiridon TsavachidisDan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States of America.
Jill KuzniarekClinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuEST), Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America.
David J RamseyClinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuEST), Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America.
Donna L WhiteSection of Gastroenterology and Hepatology, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America ; Clinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuEST), Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America ; Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States of America ; Texas Medical Center Digestive Disease Center, Houston, Texas, United States of America ; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States of America.

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Hashem B El-Serag · 2001 to 2026
$28.3M
Genetic Epidemiology of HCV-related Liver DiseaseK01DK081736 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI WHITE, DONNA LORRAINE · 2008 to 2012
$790k
Genome-wide genetic variation in the human immune response to influenza vaccinesK23AI087821 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI FRANCO, LUIS MIGUEL · 2010 to 2013
$526k
Androgen Receptor Pathway and Risk of Hepatic Fibrosis in Hepatitis CR03DK095082 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI WHITE, DONNA LORRAINE · 2013 to 2014
$153k
NIAID NIH HHS K23 AI 087821NIAID NIH HHS K23 AI087821NIDDK NIH HHS K01 DK081736NIDDK NIH HHS K24 DK04-107NIDDK NIH HHS P30 DK056338NIDDK NIH HHS P30 DK56338NIDDK NIH HHS R03 DK095082
6 · The paper itself

Abstract

backgroundChronic hepatitis C infection is the leading cause of hepatocellular carcinoma (HCC), a highly lethal malignancy with rapidly increasing prevalence in the United States. Little is known about genetic variations and HCC risk. This study aimed to determine if genetic variation in Wnt signaling pathway genes are associated with advanced hepatic fibrosis and inflammation risk in a hepatitis C virus (HCV) infected population.

methodsWe performed a genetic association cross-sectional study evaluating single nucleotide polymorphisms (SNPs) in 58 candidate genes and risk of FibroSURE-Acti Test determined advanced fibrosis (F3/F4-F4 advanced cases vs. F0-F3 mild controls) and inflammation (A2/A3-A3 advanced cases vs. A0-A2 mild controls). We calculated odds ratios (ORs) and 95% confidence intervals (CIs) employing multivariate logistic regression. Haplotypes were inferred by the HAPLO.STAT program, interactions were evaluated using multifactor dimensionality reduction (MDR) analysis.

resultsAmong 425 chronically HCV-infected male veterans, 155 (37%) had advanced fibrosis and 180 (42%) had advanced inflammation. Of 3016 SNPs evaluated, eight were significantly associated with fibrosis risk (e.g., SFRP2 rs11937424: OR = 2.19, 95% CI 1.48-3.23, P = 0.00004), and seven were significantly associated with inflammation risk (e.g., SFRP1 rs16890282: OR = 2.15, 95% CI 1.39-3.16, P = 0.0004). MDR analysis identified overweight/obese, SOST rs1405952, SFRP2 rs11937424, and FZD4 rs11234870 as the best interaction model for predicting risk of fibrosis; whereas race/ethnicity, FZD1 rs1346665, and TBX3 rs1520177 as the best interaction model for predicting risk of inflammation.

conclusionsPolymorphisms in several genes involved in the Wnt signaling pathway were associated with hepatic fibrosis or inflammation risk in HCV-infected males. Additional studies in other multi-ethnic HCV cohorts are needed to validate our findings in males and to assess if similar associations exist in chronically HCV-infected females.

Indexed as

HepacivirusPolymorphism, GeneticAdultAgedCross-Sectional StudiesHepatitis C, ChronicHumansInflammationLiver CirrhosisMaleMiddle AgedWnt Signaling Pathway

Identifiers

PMID24386373
PMCPMC3875538

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.